全球约有3.5亿人为乙型肝炎病毒(HBV)慢性感染者,而中国有约9 300万慢性乙型肝炎患者,有15%~40%未经抗病毒治疗的患者将进展为终末期肝病,如肝硬化、肝衰竭及肝癌等[1]。在中国,HBV感染相关的肝衰竭患者占肝衰竭患者总数的70%~80%[2]。HBV相关的肝衰竭的发病机制目前尚不十分清楚,主要与HBV感染本身及机体免疫反应有关[3],一些因素会诱发和加重病情,如劳 About 350 million people worldwide are chronically infected with hepatitis B virus. In China, there are about 93 million chronic hepatitis B patients. Fifteen to 40% of those without antiviral therapy will progress to end-stage liver disease, Such as cirrhosis, liver failure and liver cancer [1]. In China, HBV-related liver failure accounts for 70% to 80% of the total number of patients with liver failure [2]. The pathogenesis of HBV-related liver failure is not yet clear, mainly related to HBV infection and the body’s immune response [3], some factors will induce and aggravate the disease, such as labor